Long COVID: Current research on risk factors, pathophysiology, and emerging treatments

   Rated 5 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

1 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
1 mins

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 mins

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 mins

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

In this episode:

  • Why Long COVID is a large and growing concern as new insights emerge at great speed
  • Understand the proposed mechanisms driving Long COVID, including the two main mechanisms of persistent infection and the role of toxic fibrin induced vascular damage
  • How to clinically assess Long COVID in patients
  • Role of antivirals in reducing the duration, severity and potentially preventing the impact of Long COVID
  • Three hierarchical drivers of preventing the impact of Long COVID, how can this messaging help your patient
  • What should be your tool kit of prevention, when explaining Long COVID to your patients, especially the vulnerable ones
  • Risk of long lasting viraemia in the body causing future chronic conditions
  • Use of CoRiCal, a COVID calculator (including Long COVID); beneficial as a tool in your practice

 

Experts: Prof Brendan Crabb AC, Infectious Disease Researcher
A/Prof John Litt AM, GP and Public Health Physician

Host: Dr David Lim, GP and Medical Educator

Total time: 54 mins

 

Recommended resources:

Last Updated: 6 Dec, 2024

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopause and MHT: Maximising Benefits & Minimising Risks

Dr Fiona Chan

Dr Fiona Chan

Multiple Sclerosis vs Antibody Disease – What GPs Need to Know

Prof Andrew Sindone & Dr Ted Wu

Prof Andrew Sindone & Dr Ted Wu

Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs

Dr Shannon Thomas

Dr Shannon Thomas

Peripheral Arterial Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Brendan Crabb AC

expert

Prof Brendan Crabb AC

Infectious Disease Researcher; Director and CEO, Burnet Institute; President, Australian Global Health Alliance, Pacific Friends of Global Health

A/Prof John Litt AM

expert

A/Prof John Litt AM

GP; Public Health Physician; Associate Professor in the Discipline of General Practice, Flinders University

Recent articles

Find your area of interest

Share this

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease